A new review from the Cochrane Database of Systematic Reviews confirms that antidepressants can effectively reduce symptoms of generalized anxiety disorder (GAD) in clinical trials. However, there is ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Results showed that antidepressants were more effective than placebo in reducing anxiety symptoms, with a 41% higher response rate among those taking the medication compared to those taking a placebo.

Anxiety treatment can take place with the help of ... such as a high heart rate, feelings of depression, sleeping difficulties, or suicidal thoughts, visit their doctors. Doctors can then identify ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.